Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN103 in Newly Treated Gaucher Disease
NCT05447494Phase 2Unknown
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of velaglucerase beta in Gaucher disease type 1 (GD1), Gaucher disease type 3, sponsored by CANbridge Pharmaceuticals Inc.. Status: unknown.
02
Drugs
velaglucerase beta
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on NCT05447494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447494.